Jörn Markus Schattenberg (J M Schattenberg, Jorn Schattenberg, Joern M Schattenberg, Jörn M Schattenberg, Jörn Schattenberg)

Loop profile Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2015-2023
Publications (10 Years): 99

Top Topics

Systematic Review

Top Venues

Liver international : official journal of the International Association for the Study of the Liver

Alimentary pharmacology & therapeutics

Hepatology communications

This page only lists publications with an associated author ORCID identifier.

Publications

Markus Schepers, Irene Schmidtmann, Daniela Zahn, Philipp Wild, Manfred Beutel, Alexander K Schuster, Thomas Münzel, Karl J Lackner, Katharina Geschke, Jörn Markus Schattenberg, Rieke Baumkötter, Simge Yilmaz, Daniel Wollschläger
Medical appointments and provision of medical care during the COVID-19 pandemic in Mainz, Germany. PloS one 18 (1) (2023)
Joost Boeckmans, Jörn Markus Schattenberg
Fatty liver disease at the basis of cardiac remodelling and increased heart rate: insights from the UK Biobank. Liver international : official journal of the International Association for the Study of the Liver (2023)
Philip Noel Newsome, Arun J Sanyal, Guy Neff, Jörn Markus Schattenberg, Vlad Ratziu, Judith Ertle, Jasmin Link, Alison Mackie, Corinna Schoelch, Eric Lawitz, null null
A randomised Phase IIa trial of amine oxidase copper-containing 3 (AOC3) inhibitor BI 1467335 in adults with non-alcoholic steatohepatitis. Nature communications 14 (1) (2023)
Johanna Schönau, Axel Wester, Hannes Hagström, Jörn Markus Schattenberg
Authors reply: Risk of fractures and postfracture mortality in 3980 people with primary biliary cholangitis. Journal of internal medicine (2023)
Joost Boeckmans, Alexandra Gatzios, Jörn Markus Schattenberg, Robim Marcelino Rodrigues, Vera Rogiers, Tamara Vanhaecke
Pharmacogenetics in early drug development for non-alcoholic steatohepatitis: missed chances and future opportunities. Archives of toxicology (2023)
Markus Schepers, Irene Schmidtmann, Daniela Zahn, Philipp Wild, Manfred Beutel, Alexander K Schuster, Thomas Münzel, Karl J Lackner, Katharina Geschke, Jörn Markus Schattenberg, Rieke Baumkötter, Simge Yilmaz, Daniel Wollschläger
Medical appointments and provision of medical care during the COVID-19 pandemic in Mainz, Germany. PloS one 18 (1) (2023)
Kris V Kowdley, Christopher L Bowlus, Cynthia Levy, Ulus S Akarca, Mario Reis Alvares-da-Silva, Pietro Andreone, Marco Arrese, Christophe Corpechot, Sven M Francque, Michael A Heneghan, Pietro Invernizzi, David Jones, Frederik C Kruger, Eric Lawitz, Marlyn J Mayo, Mitchell L Shiffman, Mark G Swain, José Miguel Valera, Victor Vargas, John M Vierling, Alejandra Villamil, Carol Addy, Julie Dietrich, Jean-Michel Germain, Sarah Mazain, Dragutin Rafailovic, Bachirou Taddé, Benjamin Miller, Jianfen Shu, Claudia O Zein, Jörn Markus Schattenberg, null null
Efficacy and Safety of Elafibranor in Primary Biliary Cholangitis. The New England journal of medicine (2023)
Joost Boeckmans, Alexandra Gatzios, Jörn Markus Schattenberg, Robim Marcelino Rodrigues, Vera Rogiers, Tamara Vanhaecke
Pharmacogenetics in early drug development for non-alcoholic steatohepatitis: missed chances and future opportunities. Archives of toxicology 97 (6) (2023)
Markus Schepers, Irene Schmidtmann, Daniela Zahn, Philipp Wild, Manfred Beutel, Alexander K Schuster, Thomas Münzel, Karl J Lackner, Katharina Geschke, Jörn Markus Schattenberg, Rieke Baumkötter, Simge Yilmaz, Daniel Wollschläger
Medical appointments and provision of medical care during the COVID-19 pandemic in Mainz, Germany. PloS one 18 (1) (2023)
Arunkumar Krishnan, Carolin V Schneider, Jörn Markus Schattenberg, Saleh A Alqahthani
Risk of severe disease and mortality of COVID-19 in patients with Budd-Chiari syndrome: A population-based matched cohort study. Liver international : official journal of the International Association for the Study of the Liver (2023)
Markus Schepers, Irene Schmidtmann, Daniela Zahn, Philipp Wild, Manfred Beutel, Alexander K Schuster, Thomas Münzel, Karl J Lackner, Katharina Geschke, Jörn Markus Schattenberg, Rieke Baumkötter, Simge Yilmaz, Daniel Wollschläger
Medical appointments and provision of medical care during the COVID-19 pandemic in Mainz, Germany. PloS one 18 (1) (2023)
Joost Boeckmans, Jörn Markus Schattenberg
Fatty liver disease at the basis of cardiac remodelling and increased heart rate: Insights from the UK Biobank. Liver international : official journal of the International Association for the Study of the Liver (2023)
Olivier Govaere, Megan S R Hasoon, Leigh Alexander, Simon J Cockell, Dina Tiniakos, Mattias Ekstedt, Jörn Markus Schattenberg, Jerome Boursier, Elisabetta Bugianesi, Vlad Ratziu, null null, Ann K Daly, Quentin Mark Anstee
A proteo-transcriptomic map of non-alcoholic fatty liver disease signatures. Nature metabolism (2023)
Stephen A Harrison, Vlad Ratziu, Quentin Mark Anstee, Mazen Noureddin, Arun J Sanyal, Jörn Markus Schattenberg, Pierre Bedossa, Mustafa R Bashir, David Schneider, Rebecca Taub, Meena Bansal, Kris V Kowdley, Zobair M Younossi, Rohit Loomba
Design of the phase 3 MAESTRO clinical program to evaluate resmetirom for the treatment of nonalcoholic steatohepatitis. Alimentary pharmacology & therapeutics (2023)
Arunkumar Krishnan, Carolin V Schneider, Jörn Markus Schattenberg, Saleh A Alqahthani
Research Letters: Risk of severe disease and mortality of COVID-19 in patients with Budd-Chiari syndrome: A Population-Based Matched Cohort Study. Liver international : official journal of the International Association for the Study of the Liver (2023)
Joost Boeckmans, Alexandra Gatzios, Jörn Markus Schattenberg, Robim Marcelino Rodrigues, Vera Rogiers, Tamara Vanhaecke
Pharmacogenetics in early drug development for non-alcoholic steatohepatitis: missed chances and future opportunities. Archives of toxicology 97 (6) (2023)
Jeffrey Victor Lazarus, Hannah Han, Henry E Mark, Saleh A Alqahtani, Jörn Markus Schattenberg, Joan B Soriano, Trenton M White, Shira Zelber-Sagi, M Ashworth Dirac, null null
The global fatty liver disease Sustainable Development Goal country score for 195 countries and territories. Hepatology (Baltimore, Md.) 78 (3) (2023)
Joost Boeckmans, Alexandra Gatzios, Jörn Markus Schattenberg, Ger H Koek, Robim Marcelino Rodrigues, Tamara Vanhaecke
PNPLA3 I148M and response to treatment for hepatic steatosis: A systematic review. Liver international : official journal of the International Association for the Study of the Liver (2023)
Johanna Schönau, Axel Wester, Jörn Markus Schattenberg, Hannes Hagström
Risk of fractures and postfracture mortality in 3980 people with primary biliary cholangitis: A population-based cohort study. Journal of internal medicine (2023)
Joost Boeckmans, Alexandra Gatzios, Jörn Markus Schattenberg, Ger H Koek, Robim M Rodrigues, Tamara Vanhaecke
PNPLA3 I148M and response to treatment for hepatic steatosis. A systematic review. Liver international : official journal of the International Association for the Study of the Liver (2023)
Johanna Schönau, Axel Wester, Jörn Markus Schattenberg, Hannes Hagström
Risk of fractures and post-fracture mortality in 3,980 people with Primary Biliary Cholangitis: A population-based cohort study. Journal of internal medicine (2023)
Joost Boeckmans, Alexandra Gatzios, Jörn Markus Schattenberg, Ger H Koek, Robim Marcelino Rodrigues, Tamara Vanhaecke
PNPLA3 I148M and response to treatment for hepatic steatosis: A systematic review. Liver international : official journal of the International Association for the Study of the Liver (2023)
Simon Johannes Gairing, Eva M Schleicher, Leonard Kaps, Sophia Schulte-Beerbuehl, Kristina Steiner, Christian Labenz, Jörn Markus Schattenberg, Peter R Galle, Marcus-Alexander Wörns, Christian Labenz
Development and evaluation of a virtual reality driving test for patients with cirrhosis. Hepatology communications 7 (11) (2023)
Joost Boeckmans, Laurent Sandrin, Christian Knackstedt, Jörn Markus Schattenberg
Liver stiffness as a cornerstone in heart disease risk assessment. Liver international : official journal of the International Association for the Study of the Liver (2023)
Andreas Teufel, Andreas Geier, Christoph Sarrazin, Jörn Markus Schattenberg, Achim Kautz, Rebecca Dorner, Jan Kramer, Katrin Jerysiak, Theodor Baars, Bastian Hönscheid, Dirk Müller-Wieland, Siegbert Rossol, Christian Trautwein, Frank Tacke, Peter Lemmer
[Intersectoral management of patients with abnormal liver enzymes and non-alcoholic fatty liver disease (NAFLD)]. Zeitschrift fur Gastroenterologie (2023)
Markus Schepers, Irene Schmidtmann, Daniela Zahn, Philipp Wild, Manfred Beutel, Alexander K Schuster, Thomas Münzel, Karl J Lackner, Katharina Geschke, Jörn Markus Schattenberg, Rieke Baumkötter, Simge Yilmaz, Daniel Wollschläger
Medical appointments and provision of medical care during the COVID-19 pandemic in Mainz, Germany. PloS one 18 (1) (2023)
Martin Franck, Katharina John, Sherin Al Aoua, Monika Rau, Andreas Geier, Jörn Markus Schattenberg, Heiner Wedemeyer, Klaus Schulze-Osthoff, Heike Bantel
Hepatokine-based identification of fibrotic NASH and improved risk stratification in a multicentre cohort of NAFLD patients. Liver international : official journal of the International Association for the Study of the Liver (2023)
Joost Boeckmans, Alexandra Gatzios, Jörn Markus Schattenberg, Ger H Koek, Robim Marcelino Rodrigues, Tamara Vanhaecke
PNPLA3 I148M and response to treatment for hepatic steatosis: A systematic review. Liver international : official journal of the International Association for the Study of the Liver (2023)
Joost Boeckmans, Alexandra Gatzios, Jörn Markus Schattenberg, Robim Marcelino Rodrigues, Vera Rogiers, Tamara Vanhaecke
Pharmacogenetics in early drug development for non-alcoholic steatohepatitis: missed chances and future opportunities. Archives of toxicology 97 (6) (2023)
Omar Hahad, Volker H Schmitt, Natalie Arnold, Karsten Keller, Jürgen H Prochaska, Philipp S Wild, Andreas Schulz, Karl J Lackner, Norbert Pfeiffer, Irene Schmidtmann, Matthias Michal, Jörn Markus Schattenberg, Oliver Tüscher, Andreas Daiber, Thomas Münzel
Chronic cigarette smoking is associated with increased arterial stiffness in men and women: evidence from a large population-based cohort. Clinical research in cardiology : official journal of the German Cardiac Society (2022)
Dirk Andreas Ridder, Lana Louisa Urbansky, Hagen Roland Witzel, Mario Schindeldecker, Arndt Weinmann, Kristina Berndt, Tiemo Sven Gerber, Bruno Christian Köhler, Federico Nichetti, Annekathrin Ludt, Nadine Gehrke, Jörn Markus Schattenberg, Stefan Heinrich, Wilfried Roth, Beate Katharina Straub
Transforming Growth Factor-β Activated Kinase 1 (Tak1) Is Activated in Hepatocellular Carcinoma, Mediates Tumor Progression, and Predicts Unfavorable Outcome. Cancers 14 (2) (2022)
Maurice Michel, Alisha Wahl, Malena Anders, Saleh A Alqahtani, Wolfgang M Kremer, Peter R Galle, Christian Labenz, Daniel Grimm, Martin Sprinzl, Jörn Markus Schattenberg
Significant liver fibrosis is a predictor of poor health-related quality of life in people living with HIV. Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation (2022)
Nadine Gehrke, Marcus A Wörns, Amrit Mann, Nadine Hövelmeyer, Esther Von Stebut, Beate K Straub, Peter R Galle, Jörn Markus Schattenberg
Hepatocyte Bcl-3 protects from death-receptor mediated apoptosis and subsequent acute liver failure. Cell death & disease 13 (5) (2022)
Eva Maria Schleicher, Simon Johannes Gairing, Peter Robert Galle, Julia Weinmann-Menke, Jörn Markus Schattenberg, Karel Kostev, Christian Labenz
A higher FIB-4 index is associated with an increased incidence of renal failure in the general population. Hepatology communications 6 (12) (2022)
Nadine Gehrke, Lea J Hofmann, Beate K Straub, Frank Rühle, Ari Waisman, Peter R Galle, Jörn Markus Schattenberg
Hepatic interleukin-1 receptor type 1 signalling regulates insulin sensitivity in the early phases of nonalcoholic fatty liver disease. Clinical and translational medicine 12 (9) (2022)
Simon Johannes Gairing, Julian Anders, Leonard Kaps, Michael Nagel, Maurice Michel, Wolfgang Maximilian Kremer, Max Hilscher, Peter Robert Galle, Jörn Markus Schattenberg, Marcus-Alexander Wörns, Christian Labenz
Evaluation of IL-6 for Stepwise Diagnosis of Minimal Hepatic Encephalopathy in Patients With Liver Cirrhosis. Hepatology communications 6 (5) (2022)
Vlad Ratziu, Quentin Mark Anstee, Vincent Wai-Sun Wong, Jörn Markus Schattenberg, Elisabetta Bugianesi, Salvador Augustin, Liana Gheorghe, Vittoria Zambon, Nancy S Reau
An international survey on patterns of practice in NAFLD and expectations for therapies-The POP-NEXT project. Hepatology (Baltimore, Md.) 76 (6) (2022)
Leonard Kaps, Lejla Lukac, Maurice Michel, Wolfgang Maximilian Kremer, Max Hilscher, Simon Johannes Gairing, Peter Robert Galle, Jörn Markus Schattenberg, Marcus-Alexander Wörns, Michael Nagel, Christian Labenz
Liver Frailty Index for Prediction of Short-Term Rehospitalization in Patients with Liver Cirrhosis. Diagnostics (Basel, Switzerland) 12 (5) (2022)
Maurice Michel, Christian Labenz, Malena Anders, Alisha Wahl, Lisann Girolstein, Leonard Kaps, Wolfgang M Kremer, Yvonne Huber, Peter R Galle, Martin Sprinzl, Jörn Markus Schattenberg
Effect of hepatic steatosis and associated metabolic comorbidities on health-related quality of life in people living with HIV. Hepatology communications 6 (8) (2022)
Simon Johannes Gairing, Eva Maria Schleicher, Lukas Müller, Christian Labenz, Felix Darstein, Daniel Grimm, Visvakanth Sivanathan, Arndt Weinmann, Marcus-Alexander Wörns, Roman Kloeckner, Michael B Pitton, Florian Thieringer, Khan Fareed Rahman, Peter Robert Galle, Jörn Markus Schattenberg, Friedrich Förster
Bevacizumab in combination with octreotide rescues a patient with liver cirrhosis, GAVE syndrome and refractory hemorrhage - a case report. Zeitschrift fur Gastroenterologie (2022)
Katharina John, Martin Franck, Sherin Al Aoua, Monika Rau, Yvonne Huber, Jörn Markus Schattenberg, Andreas Geier, Matthias J Bahr, Heiner Wedemeyer, Klaus Schulze-Osthoff, Heike Bantel
Non-Invasive Detection of Fibrotic NASH in NAFLD Patients with Low or Intermediate FIB-4. Journal of clinical medicine 11 (15) (2022)
Simon Johannes Gairing, Jörn Markus Schattenberg
The unmet need of personalized HCC screening-Lessons learned from the Swedish nationwide registries. United European gastroenterology journal 10 (5) (2022)
Yvonne Huber, Andreas Schulz, Irene Schmidtmann, Manfred Beutel, Norbert Pfeiffer, Thomas Münzel, Peter R Galle, Philipp S Wild, Karl J Lackner, Jörn Markus Schattenberg
Prevalence and Risk Factors of Advanced Liver Fibrosis in a Population-Based Study in Germany. Hepatology communications 6 (6) (2022)
Jeffrey Victor Lazarus, Henry E Mark, Massimo G Colombo, Alessandro Rhyl Demaio, John F Dillon, Jacob George, Hannes Hagström, Samantha L Hocking, Nancy Lee, Mark J Nieuwenhuijsen, Mary E Rinella, Manuel Romero, Joan B Soriano, Jörn Markus Schattenberg, Frank Tacke, Emmanuel A Tsochatzis, Luca Vittorio Valenti, Shira Zelber-Sagi, M Ashworth Dirac, Terry T K Huang
A sustainable development goal framework to guide multisectoral action on NAFLD through a societal approach. Alimentary pharmacology & therapeutics (2021)
Jeffrey Victor Lazarus, Quentin Mark Anstee, Hannes Hagström, Kenneth Cusi, Helena Cortez-Pinto, Henry E Mark, Michael Roden, Emmanuel A Tsochatzis, Vincent Wai-Sun Wong, Zobair M Younossi, Shira Zelber-Sagi, Manuel Romero, Jörn Markus Schattenberg
Defining comprehensive models of care for NAFLD. Nature reviews. Gastroenterology & hepatology 18 (10) (2021)
Olivier Govaere, Simon J Cockell, Dina Tiniakos, Rachel Queen, Ramy Younes, Michele Vacca, Leigh Alexander, Federico Ravaioli, Jeremy Palmer, Salvatore Petta, Jerome Boursier, Chiara Rosso, Katherine Johnson, Kristy Wonders, Christopher P Day, Mattias Ekstedt, Matej Oresic, Rebecca Darlay, Heather J Cordell, Fabio Marra, Antonio Vidal-Puig, Pierre Bedossa, Jörn Markus Schattenberg, Karine Clement, Michael E D Allison, Elisabetta Bugianesi, Vlad Ratziu, Ann K Daly, Quentin Mark Anstee
Transcriptomic profiling across the nonalcoholic fatty liver disease spectrum reveals gene signatures for steatohepatitis and fibrosis. Science translational medicine 12 (572) (2021)
Pere Ginès, Laurent Castera, Frank Lammert, Isabel Graupera, Miquel Serra-Burriel, Alina M Allen, Vincent Wai-Sun Wong, Phillipp Hartmann, Maja Thiele, Llorenç Caballeria, Robert J de Knegt, Ivica Grgurevic, Salvador Augustin, Emmanuel A Tsochatzis, Jörn Markus Schattenberg, Indra Neil Guha, Andrea Martini, Rosa M Morillas, Montserrat Garcia-Retortillo, Harry de Koning, Núria Fabrellas Padrés, Judit Pich, Ann T Ma, M Alba Diaz, Dominique Roulot, Philip Noel Newsome, Michael Manns, Patrick S Kamath, Aleksander Krag, null null
Population screening for liver fibrosis: Toward early diagnosis and intervention for chronic liver diseases. Hepatology (Baltimore, Md.) (2021)
Saleh A Alqahtani, Jörn Markus Schattenberg
Nonalcoholic fatty liver disease: use of diagnostic biomarkers and modalities in clinical practice. Expert review of molecular diagnostics 21 (10) (2021)
Christian Labenz, Jörn Markus Schattenberg
Letter: proton pump inhibitor use and bone fracture risk-a mechanistic point of view. Authors' reply. Alimentary pharmacology & therapeutics 53 (5) (2021)
Maurice Michel, Francesca Spinelli, Annette Grambihler, Christian Labenz, Michael Nagel, Leonard Kaps, Yvonne Huber, Peter R Galle, Marcus-Alexander Wörns, Jörn Markus Schattenberg
Health-related quality of life in patients with autoimmune hepatitis. Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation 30 (10) (2021)
Anne-Marieke Van Dijk, Jörn Markus Schattenberg, Adriaan G Holleboom, Maarten E Tushuizen
Referral care paths for non-alcoholic fatty liver disease-Gearing up for an ever more prevalent and severe liver disease. United European gastroenterology journal 9 (8) (2021)
Simon Johannes Gairing, Peter Robert Galle, Jörn Markus Schattenberg, Karel Kostev, Christian Labenz
Portal Vein Thrombosis Is Associated with an Increased Incidence of Depression and Anxiety Disorders. Journal of clinical medicine 10 (23) (2021)
Angelo Armandi, Jörn Markus Schattenberg
Editorial: the polygenic risk of cirrhosis development. Alimentary pharmacology & therapeutics 53 (7) (2021)
Sven M Francque, Pierre Bedossa, Vlad Ratziu, Quentin M Anstee, Elisabetta Bugianesi, Arun J Sanyal, Rohit Loomba, Stephen A Harrison, Rozalina Balabanska, Lyudmila Mateva, Nicolas Lanthier, Naim Alkhouri, Christophe Moreno, Jörn Markus Schattenberg, Diana Stefanova-Petrova, Luisa Vonghia, Régine Rouzier, Maeva Guillaume, Alexander Hodge, Manuel Romero-Gómez, Philippe Huot-Marchand, Martine Baudin, Marie-Paule Richard, Jean-Louis Abitbol, Pierre Broqua, Jean-Louis Junien, Manal F Abdelmalek, null null
A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH. The New England journal of medicine 385 (17) (2021)
Jeffrey Victor Lazarus, Henry E Mark, Quentin Mark Anstee, Juan Pablo Arab, Rachel L Batterham, Laurent Castera, Helena Cortez-Pinto, Javier Crespo, Kenneth Cusi, M Ashworth Dirac, Sven M Francque, Jacob George, Hannes Hagström, Terry T K Huang, Mona H Ismail, Achim Kautz, Shiv Kumar Sarin, Stephen Caldwell, Veronica Miller, Philip N Newsome, Michael Ninburg, Ponsiano Ocama, Vlad Ratziu, Mary Rinella, Diana Romero, Manuel Romero, Jörn Markus Schattenberg, Emmanuel A Tsochatzis, Luca Valenti, Vincent Wai-Sun Wong, Yusuf Yilmaz, Zobair M Younossi, Shira Zelber-Sagi, null null
Advancing the global public health agenda for NAFLD: a consensus statement. Nature reviews. Gastroenterology & hepatology (2021)
Hannes Hagström, Leon A Adams, Alina M Allen, Christopher D Byrne, Yoosoo Chang, Henning Grønbæk, Mona Ismail, Peter Jepsen, Fasiha Kanwal, Jennifer R Kramer, Jeffrey Victor Lazarus, Michelle T Long, Rohit Loomba, Philip Noel Newsome, Denis Moir, Seungho Ryu, Jörn Markus Schattenberg, Marina Serper, Nick Sheron, Tracey G Simon, Elliot B Tapper, Sarah Wild, Vincent Wai-Sun Wong, Yusuf Yilmaz, Shira Zelber-Sagi, Fredrik O Åberg
Administrative Coding in Electronic Health Care Record-Based Research of NAFLD: An Expert Panel Consensus Statement. Hepatology (Baltimore, Md.) 74 (1) (2021)
Jörn Markus Schattenberg, Jeffrey Victor Lazarus, Philip N Newsome, Lawrence Serfaty, Alessio Aghemo, Salvador Augustin, Emmanuel A Tsochatzis, Victor De Ledinghen, Elisabetta Bugianesi, Manuel Romero, Heike Bantel, Stephen D Ryder, Jerome Boursier, Vincent Leroy, Javier Crespo, Laurent Castera, Lefteris Floros, Vincenzo Atella, Jorge Mestre-Ferrandiz, Rachel Elliott, Achim Kautz, Alice Morgan, Sally Hartmanis, Sharad Vasudevan, Lynne Pezzullo, Aldo Trylesinski, Sandrine Cure, Victoria Higgins, Vlad Ratziu
Disease burden and economic impact of diagnosed non-alcoholic steatohepatitis in five European countries in 2018: A cost-of-illness analysis. Liver international : official journal of the International Association for the Study of the Liver 41 (6) (2021)
Anne Linde Mak, Jenny Lee, Anne-Marieke Van Dijk, Yasaman Vali, Guruprasad P Aithal, Jörn Markus Schattenberg, Quentin Mark Anstee, M Julia Brosnan, Mohammad Hadi Zafarmand, Dewkoemar Ramsoekh, Stephen A Harrison, Max Nieuwdorp, Patrick M Bossuyt, Adriaan G Holleboom
Systematic Review with Meta-Analysis: Diagnostic Accuracy of Pro-C3 for Hepatic Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease. Biomedicines 9 (12) (2021)
Saleh A Alqahthani, Jörn Markus Schattenberg
NAFLD in the Elderly. Clinical interventions in aging 16 (2021)
Simon J Gairing, Roman Kloeckner, Michael B Pitton, Janine Baumgart, Charis von Auer-Wegener, Hauke Lang, Peter R Galle, Friedrich Foerster, Jörn Markus Schattenberg
Multidisciplinary approach to the complex treatment for non-cirrhotic portal hypertension - case-report-based discussion. Zeitschrift fur Gastroenterologie 59 (1) (2021)
Leonard Kaps, C J Ahlbrand, R Gadban, M Nagel, C Labenz, P Klimpke, S Holtz, S Boedecker, M Michel, W M Kremer, M Hilscher, P R Galle, D Kraus, Jörn Markus Schattenberg, Julia Weinmann-Menke
Applicability and safety of discontinuous ADVanced Organ Support (ADVOS) in the treatment of patients with acute-on-chronic liver failure (ACLF) outside of intensive care. PloS one 16 (4) (2021)
Christian Labenz, Karel Kostev, Angelo Armandi, Peter R Galle, Jörn Markus Schattenberg
Impact of thyroid disorders on the incidence of non-alcoholic fatty liver disease in Germany. United European gastroenterology journal (2021)
Jörn Markus Schattenberg, Quentin M Anstee, Cyrielle Caussy, Elisabetta Bugianesi, Branko Popovic
Differences between current clinical guidelines for screening, diagnosis and management of nonalcoholic fatty liver disease and real-world practice: a targeted literature review. Expert review of gastroenterology & hepatology 15 (11) (2021)
Angelo Armandi, Jörn Markus Schattenberg
Beyond the Paradigm of Weight Loss in Non-Alcoholic Fatty Liver Disease: From Pathophysiology to Novel Dietary Approaches. Nutrients 13 (6) (2021)
Leonard Kaps, Katharina Hildebrand, Michael Nagel, Maurice Michel, Wolfgang Maximilian Kremer, Max Hilscher, Peter R Galle, Jörn Markus Schattenberg, Marcus-Alexander Wörns, Christian Labenz
Risk factors for poorer health literacy in patients with liver cirrhosis. PloS one 16 (7) (2021)
Tilman Emrich, Jörn Markus Schattenberg
Letter: coronary atherosclerosis in patients with significant hepatic fibrosis in non-alcoholic fatty liver disease-the role for non-invasive testing. Alimentary pharmacology & therapeutics 54 (2) (2021)
Leonardo Ruiz-Casas, Sonia O'Hara, Claudia Mighiu, Alan Finnegan, Alison Taylor, Emily Ventura, Anil Dhawan, Karen F Murray, Jörn Markus Schattenberg, Jose Willemse, Melanie Karakaidos, Harpreet Brrang
Burden of illness of progressive familial intrahepatic cholestasis in the US, UK, France, and Germany: study rationale and protocol of the PICTURE study. Expert review of pharmacoeconomics & outcomes research 21 (2) (2021)
Katharina Bahr, Perikles Simon, Barbara Leggewie, Haralampos Gouveris, Jörn Markus Schattenberg
The Snoring Index Identifies Risk of Non-Alcoholic Fatty Liver Disease in Patients with Obstructive Sleep Apnea Syndrome. Biology 11 (1) (2021)
Christian Labenz, Karel Kostev, Leonard Kaps, Peter R Galle, Jörn Markus Schattenberg
Incident Dementia in Elderly Patients with Nonalcoholic Fatty Liver Disease in Germany. Digestive diseases and sciences 66 (9) (2020)
Jörn Markus Schattenberg
Prof Jörn Schattenberg sheds light on key treatment and diagnostic approaches to nonalcoholic steatohepatitis (NASH). Expert opinion on investigational drugs 29 (2) (2020)
Leonard Kaps, Christian Labenz, Peter R Galle, Julia Weinmann-Menke, Karel Kostev, Jörn Markus Schattenberg
Non-alcoholic fatty liver disease increases the risk of incident chronic kidney disease. United European gastroenterology journal 8 (8) (2020)
Christian Labenz, Yvonne Huber, Maurice Michel, Michael Nagel, Peter R Galle, Karel Kostev, Jörn Markus Schattenberg
Nonalcoholic Fatty Liver Disease Increases the Risk of Anxiety and Depression. Hepatology communications 4 (9) (2020)
Maurice Michel, Jörn Markus Schattenberg
[Liver-specific diagnostic for non-alcoholic fatty liver disease (NAFLD) - time to replace liver biopsy?] Zeitschrift fur Gastroenterologie 58 (12) (2020)
Saleh A Alqahtani, Jörn Markus Schattenberg
Liver injury in COVID-19: The current evidence. United European gastroenterology journal 8 (5) (2020)
Julia Dietz, Johannes Vermehren, Katrin Matschenz, Peter Buggisch, Hartwig Klinker, Julian Schulze Zur Wiesch, Holger Hinrichsen, Kai-Henrik Peiffer, Christiana Graf, Thomas Discher, Janina Trauth, Jörn Markus Schattenberg, Felix Piecha, Stefan Mauss, Claus Niederau, Tobias Mueller, Christoph Neumann-Haefelin, Christoph P Berg, Stefan Zeuzem, Christoph Sarrazin, null null
Treatment outcomes in hepatitis C virus genotype 1a infected patients with and without baseline NS5A resistance-associated substitutions. Liver international : official journal of the International Association for the Study of the Liver (2020)
Geoff Farrell, Jörn Markus Schattenberg, Isabelle Leclercq, Matthew M Yeh, Robert Goldin, Narci Teoh, Detlef Schuppan
Mouse Models of Nonalcoholic Steatohepatitis: Toward Optimization of Their Relevance to Human Nonalcoholic Steatohepatitis. Hepatology (Baltimore, Md.) 69 (5) (2020)
Maurice Michel, Jörn Markus Schattenberg
Effectiveness of lifestyle interventions in NAFLD (nonalcoholic fatty liver disease) - how are clinical trials affected? Expert opinion on investigational drugs 29 (2) (2020)
Jörn Markus Schattenberg
Prevention of endpoints in primary biliary cholangitis with ursodeoxycholic acid: quantifying the benefit. Gut 69 (8) (2020)
Jörn Markus Schattenberg
Reading the stars for hepatic fibrosis or how to predict the severity of liver disease in patients with NASH. Liver international : official journal of the International Association for the Study of the Liver 39 (5) (2020)
Christian Labenz, Michael Nagel, Wolfgang M Kremer, Max Hilscher, Caroline A Schilling, Gerrit Toenges, Robert Kuchen, Jörn Markus Schattenberg, Peter R Galle, Marcus-Alexander Wörns
Association between diabetes mellitus and hepatic encephalopathy in patients with cirrhosis. Alimentary pharmacology & therapeutics 52 (3) (2020)
Angelo Armandi, Jörn Markus Schattenberg
NAFLD between genes and environment: what drives fibrogenesis? Gut 70 (5) (2020)
Christian Labenz, Marcus-Alexander Wörns, Charles C Adarkwah, Peter R Galle, Jörn Markus Schattenberg, Karel Kostev
Proton pump inhibitors increase risk of bone fractures in men with cirrhosis: a population-based study. Alimentary pharmacology & therapeutics 52 (6) (2020)
Jörn Markus Schattenberg, Christian Labenz, Marcus-Alexander Wörns, Philipp Menge, Arndt Weinmann, Peter R Galle, Martin F Sprinzl
Patterns of liver injury in COVID-19 - a German case series. United European gastroenterology journal 8 (7) (2020)
Jeffrey Victor Lazarus, Massimo Colombo, Helena Cortez-Pinto, Terry T K Huang, Veronica Miller, Michael Ninburg, Jörn Markus Schattenberg, Lynn Seim, Vincent Wai-Sun Wong, Shira Zelber-Sagi
NAFLD - sounding the alarm on a silent epidemic. Nature reviews. Gastroenterology & hepatology 17 (7) (2020)
Joost P H Drenth, Jörn Markus Schattenberg
The nonalcoholic steatohepatitis (NASH) drug development graveyard: established hurdles and planning for future success. Expert opinion on investigational drugs 29 (12) (2020)
Christian Labenz, Jörn Markus Schattenberg
Editorial: stepwise risk stratification for both F3 and F4 in NAFLD patients-authors' reply. Alimentary pharmacology & therapeutics 48 (11-12) (2019)
Christian Labenz, Yvonne Huber, Maurice Michel, Michael Nagel, Peter R Galle, Karel Kostev, Jörn Markus Schattenberg
Impact of NAFLD on the Incidence of Cardiovascular Diseases in a Primary Care Population in Germany. Digestive diseases and sciences 65 (7) (2019)
Jörn Markus Schattenberg, Ina Bergheim
Nutritional Intake and the Risk for Non-Alcoholic Fatty Liver Disease (NAFLD). Nutrients 11 (3) (2019)
Jörn Markus Schattenberg, Mattias Ekstedt
Assessing the disease burden of non-alcoholic fatty liver disease in the real world - big data and big numbers. BMC medicine 17 (1) (2019)
Jörn Markus Schattenberg, Rohit Loomba
Refining Noninvasive Diagnostics In Nonalcoholic Fatty Liver Disease: Closing the Gap to Detect Advanced Fibrosis. Hepatology (Baltimore, Md.) 69 (3) (2019)
Yvonne Huber, Daniel Pfirrmann, Ines Gebhardt, Christian Labenz, Nadine Gehrke, Beate K Straub, Christian Ruckes, Heike Bantel, Eugenio Belda, Karine Clément, Diana J Leeming, Morten A Karsdal, Peter R Galle, Perikles Simon, Jörn Markus Schattenberg
Improvement of non-invasive markers of NAFLD from an individualised, web-based exercise program. Alimentary pharmacology & therapeutics 50 (8) (2019)
Nadine Gehrke, Jana Biedenbach, Yvonne Huber, Beate K Straub, Peter R Galle, Perikles Simon, Jörn Markus Schattenberg
Voluntary exercise in mice fed an obesogenic diet alters the hepatic immune phenotype and improves metabolic parameters - an animal model of life style intervention in NAFLD. Scientific reports 9 (1) (2019)
Leonard Kaps, Annette Grambihler, Bethlehem Yemane, Michael Nagel, Christian Labenz, Pascal Ploch, Maurice Michel, Peter R Galle, Marcus-Alexander Wörns, Jörn Markus Schattenberg
Symptom Burden and Treatment Response in Patients with Primary Biliary Cholangitis (PBC). Digestive diseases and sciences 65 (10) (2019)
Christian Labenz, Jürgen H Prochaska, Yvonne Huber, Michael Nagel, Beate K Straub, Philipp Wild, Peter R Galle, Jörn Markus Schattenberg
Cardiovascular Risk Categories in Patients With Nonalcoholic Fatty Liver Disease and the Role of Low-Density Lipoprotein Cholesterol. Hepatology communications 3 (11) (2019)
Daniel Pfirrmann, Yvonne Huber, Jörn Markus Schattenberg, Perikles Simon
Web-Based Exercise as an Effective Complementary Treatment for Patients With Nonalcoholic Fatty Liver Disease: Intervention Study. Journal of medical Internet research 21 (1) (2019)
Christian Labenz, Yvonne Huber, Eva Kalliga, Michael Nagel, Christian Ruckes, Beate K Straub, Peter R Galle, Marcus-Alexander Wörns, Quentin M Anstee, Detlef Schuppan, Jörn Markus Schattenberg
Predictors of advanced fibrosis in non-cirrhotic non-alcoholic fatty liver disease in Germany. Alimentary pharmacology & therapeutics 48 (10) (2018)
Daniel Pfirrmann, Nils Haller, Yvonne Huber, Patrick Jung, Klaus Lieb, Ines Gockel, Krystyna Poplawska, Jörn Markus Schattenberg, Perikles Simon
Applicability of a Web-Based, Individualized Exercise Intervention in Patients With Liver Disease, Cystic Fibrosis, Esophageal Cancer, and Psychiatric Disorders: Process Evaluation of 4 Ongoing Clinical Trials. JMIR research protocols 7 (5) (2018)
Nadine Gehrke, Michael Nagel, Beate K Straub, Marcus A Wörns, Marcus Schuchmann, Peter R Galle, Jörn Markus Schattenberg
Loss of cellular FLICE-inhibitory protein promotes acute cholestatic liver injury and inflammation from bile duct ligation. American journal of physiology. Gastrointestinal and liver physiology 314 (3) (2017)
Anna Janina Engstler, Tobias Aumiller, Christian Degen, Marion Dürr, Eva Weiss, Ina Barbara Maier, Jörn Markus Schattenberg, Cheng Jun Jin, Cathrin Sellmann, Ina Bergheim
Insulin resistance alters hepatic ethanol metabolism: studies in mice and children with non-alcoholic fatty liver disease. Gut 65 (9) (2015)